A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: "Sapienza Head and Neck Unit" Proposal.
dental treatment
medical report
metastatic bone cancer
oral health care delivery
osteonecrosis
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
14 02 2021
14 02 2021
Historique:
received:
06
12
2020
revised:
17
01
2021
accepted:
27
01
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
24
4
2021
Statut:
epublish
Résumé
Medication-related osteonecrosis of the jaw (MRONJ) is an adverse event associated with antiresorptive and antiangiogenic drugs. The use of these drugs in the treatment of cancer patients with bone metastasis is necessary and standardized in the literature. A multidisciplinary approach for the patient's management is strongly recommended. Therefore, it should be necessary to integrate the path of these subjects with a dedicated dental screening in order to first assess the individual risk of developing a MRONJ, and then to plan dental treatments and oral hygiene sessions, and finally to schedule a follow-up to intercept and treat early osteonecrosis. The aim of this manuscript is to propose a new simple medical report to evaluate patients affected by metastatic bone cancer in order to reduce the risk of developing MRONJ.
Identifiants
pubmed: 33672876
pii: ijerph18041851
doi: 10.3390/ijerph18041851
pmc: PMC7918934
pii:
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Oral Maxillofac Surg. 2012 Nov;41(11):1397-403
pubmed: 22840716
Case Rep Dent. 2016;2016:2856926
pubmed: 27088019
Br J Oral Maxillofac Surg. 2014 Sep;52(7):603-8
pubmed: 24856927
Oral Oncol. 2013 Sep;49(9):878-886
pubmed: 23890929
Biomedicines. 2020 Apr 24;8(4):
pubmed: 32344782
Int J Oral Maxillofac Surg. 2019 May;48(5):691-696
pubmed: 30471831
J Oral Biosci. 2019 Jun;61(2):99-104
pubmed: 31109863
Osteoporos Int. 2016 Mar;27(3):853-859
pubmed: 26493811
BMC Oral Health. 2015 Jan 20;15:5
pubmed: 25599761
Int J Dent. 2014;2014:719478
pubmed: 25328525
J Clin Oncol. 2019 Sep 1;37(25):2270-2290
pubmed: 31329513
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
Crit Rev Oncol Hematol. 2017 Dec;120:93-97
pubmed: 29198342
Oncology. 2009;76(3):209-11
pubmed: 19212145
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
Clin Ter. 2017 Jul-Aug;168(4):e253-e257
pubmed: 28703840
Biomed Res Int. 2017;2017:8136878
pubmed: 28337459
Photomed Laser Surg. 2011 Jul;29(7):447-52
pubmed: 21235406
Clin Ter. 2017 Nov-Dec;168(6):e392-e396
pubmed: 29209690
Mayo Clin Proc. 2008 Sep;83(9):1032-45
pubmed: 18775204
Oral Dis. 2012 Sep;18(6):621-3
pubmed: 22353421
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
pubmed: 12966493
Biol Pharm Bull. 2015;38(12):1850-5
pubmed: 26632176
Int J Environ Res Public Health. 2020 Aug 18;17(16):
pubmed: 32824826
Support Care Cancer. 2016 Jan;24(1):447-455
pubmed: 26335402
J Clin Oncol. 2011 Mar 20;29(9):1125-32
pubmed: 21343556
Minerva Stomatol. 2016 Feb;65(1):17-32
pubmed: 26862694
Clin Ter. 2019 Sep-Oct;170(5):e345-e351
pubmed: 31612191
Ann Oncol. 2012 May;23(5):1341-1347
pubmed: 21986094
Crit Rev Oncol Hematol. 2017 May;113:151-155
pubmed: 28427504
Br J Oral Maxillofac Surg. 2015 Jan;53(1):13-7
pubmed: 25282593
Cancer Treat Rev. 2001 Jun;27(3):165-76
pubmed: 11417967
Cancers (Basel). 2020 Jul 18;12(7):
pubmed: 32708374
Eur Rev Med Pharmacol Sci. 2016 Sep;20(17):3523-7
pubmed: 27649650